logo
Plus   Neg
Share
Email

Abu Dhabi's Mubadala To Invest About $1.2 Bln In India's Reliance Jio

Billionaire Mukesh Ambani's Reliance Industries Limited said that the Abu Dhabi-based sovereign investor, Mubadala Investment Company, will invest 9,093.60 crore Indian rupees or about $1.2 billion in its Jio Platforms Ltd.

According to Reliance Industries, the investment values Jio Platforms at an equity value of 4.91 lakh crore rupees and an enterprise value of 5.16 lakh crore rupees.

Mubadala's investment represents a 1.85% equity stake in the Indian telecom operator Jio, which has more than 388 million subscribers.

Reliance Industries stated that Jio Platforms has raised 87,655.35 crore rupees from global investors including Facebook, Silver Lake, Vista Equity Partners, General Atlantic, KKR and Mubadala in less than six weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd. Avalon Furniture is recalling about 9,500 units of Cottage Town Bedroom Furniture collection sold through Rooms To Go due to violation of federal lead paint ban, the U.S. Consumer Product Safety Commission said in a statement. According to the agency, the base coat paint used on pieces within the furniture collection contains levels of lead that exceed the federal lead paint standard. Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints. In the trial, Kevzara was added to best supportive care compared to best supportive care alone (placebo). The companies have stopped the U.S. trial.
Follow RTT